Well we knew this was coming so no surprise here. Wonder if Hendrik will be able to accomplish one thing on his to do list and get the pps up so that Cytori is not delisted and that perhaps a reverse split can be avoided. Looks like from the comments on Japan post that more doubt that this will be a a revenue generater for Cytori and instead just another bull shit fantancy told to us by mangement which eventually is proven to be a tall tale. I don'tknow with all the talk of the relationship with Japan and involvement in the process to have nothing come of this will be too much to bear for any holder of this worhless pos. Happy Thanks Giving All,but not much at all to be thankful for when it comes to this investment.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or S
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 20, 2014, Cytori Therapeutics, Inc., a Delaware corporation (the "Company"), received a letter (the "Notice") from the Listing Qualifications staff of The NASDAQ Stock Market LLC ("Nasdaq") indicating that, based upon the market value of the Company's listed securities for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum Market Value of Listed Securities ("MVLS") of $ 50,000,000, as set forth in Nasdaq Listing Rule 5450(b)(2)(A).
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until May 19, 2015, in which to regain compliance. In order to regain compliance with the minimum MVLS, the Company's MVLS must be at least $ 50,000,000 for a minimum of ten consecutive business days during this 180-day period. In the event that the Company does not regain compliance within this 180-day period, the Company may be eligible to seek an additional compliance period of 180 calendar days if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Global Market, with the exception of the bid price requirement, and provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice to the Company that its common stock will be subject to delisting.
The Notice does not result in the immediate delisting of the Company's common stock from the Nasdaq Global Market. The Company intends to monitor the Company's MVLS to allow a reasonable period for the price to rebound from its recent decline but will continue to consider its available options to regain compliance. There can be no assurance that the Company will be able to regain compliance with the minimum MVLS requirement or maintain compliance with the other listing requirements.